Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney | 3 | 2024 | 51 | 0.960 |
Why?
|
| Liver | 2 | 2024 | 49 | 0.920 |
Why?
|
| Nanoparticles | 2 | 2024 | 69 | 0.860 |
Why?
|
| Drug Delivery Systems | 2 | 2022 | 26 | 0.840 |
Why?
|
| Oils, Volatile | 1 | 2022 | 3 | 0.730 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 15 | 0.710 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1 | 0.710 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 10 | 0.690 |
Why?
|
| Central Nervous System Diseases | 1 | 2021 | 2 | 0.680 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 7 | 0.670 |
Why?
|
| Peptides | 1 | 2021 | 49 | 0.650 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 11 | 0.470 |
Why?
|
| Animals | 11 | 2024 | 1711 | 0.420 |
Why?
|
| Mice | 8 | 2024 | 685 | 0.420 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2024 | 7 | 0.400 |
Why?
|
| Neoplasms | 3 | 2024 | 90 | 0.350 |
Why?
|
| Humans | 12 | 2024 | 4936 | 0.340 |
Why?
|
| Brain | 2 | 2024 | 195 | 0.320 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 13 | 0.260 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2024 | 2 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 18 | 0.220 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2024 | 8 | 0.220 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2024 | 1 | 0.220 |
Why?
|
| Spleen | 1 | 2024 | 1 | 0.220 |
Why?
|
| Antidepressive Agents | 1 | 2024 | 14 | 0.210 |
Why?
|
| Polymyxins | 1 | 2023 | 5 | 0.200 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 14 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 6 | 0.190 |
Why?
|
| Spatial Analysis | 1 | 2022 | 2 | 0.190 |
Why?
|
| Female | 7 | 2024 | 2523 | 0.190 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 20 | 0.180 |
Why?
|
| Emulsions | 1 | 2022 | 2 | 0.180 |
Why?
|
| Solubility | 1 | 2022 | 10 | 0.180 |
Why?
|
| Lung | 1 | 2022 | 35 | 0.180 |
Why?
|
| Particle Size | 1 | 2022 | 41 | 0.180 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 3 | 0.170 |
Why?
|
| Flow Cytometry | 1 | 2021 | 39 | 0.170 |
Why?
|
| Fusobacterium nucleatum | 1 | 2021 | 2 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 32 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 8 | 0.170 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 12 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 12 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 25 | 0.170 |
Why?
|
| Inflammation | 1 | 2021 | 57 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2021 | 47 | 0.160 |
Why?
|
| Diphosphonates | 1 | 2019 | 2 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2019 | 2 | 0.160 |
Why?
|
| Drug Compounding | 1 | 2019 | 3 | 0.160 |
Why?
|
| Drug Discovery | 1 | 2019 | 15 | 0.160 |
Why?
|
| Liposomes | 1 | 2019 | 24 | 0.150 |
Why?
|
| Cricetinae | 3 | 2024 | 21 | 0.150 |
Why?
|
| Purines | 1 | 2018 | 4 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2018 | 5 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 69 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 7 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 184 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 96 | 0.130 |
Why?
|
| Male | 4 | 2024 | 2491 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 2 | 2024 | 21 | 0.100 |
Why?
|
| Rats | 2 | 2024 | 241 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 25 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2022 | 216 | 0.080 |
Why?
|
| Isoquinolines | 1 | 2024 | 5 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 6 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2024 | 4 | 0.050 |
Why?
|
| Mesocricetus | 1 | 2024 | 4 | 0.050 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2024 | 4 | 0.050 |
Why?
|
| Nucleotides, Cyclic | 1 | 2024 | 4 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 10 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2024 | 16 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 26 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 46 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 160 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 8 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2024 | 47 | 0.050 |
Why?
|
| Amikacin | 1 | 2023 | 7 | 0.050 |
Why?
|
| Models, Animal | 1 | 2023 | 24 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2023 | 17 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2023 | 28 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2023 | 125 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 225 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 3 | 0.050 |
Why?
|
| Tyrosine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 9 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 12 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2022 | 48 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2021 | 1 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2021 | 1 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 4 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2021 | 4 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2021 | 7 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2021 | 6 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2021 | 11 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2021 | 1 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2021 | 2 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 176 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2021 | 9 | 0.040 |
Why?
|
| Culture Media | 1 | 2021 | 18 | 0.040 |
Why?
|
| Intestines | 1 | 2021 | 15 | 0.040 |
Why?
|
| Colon | 1 | 2021 | 7 | 0.040 |
Why?
|
| Cricetulus | 1 | 2021 | 18 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 37 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 31 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 19 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 127 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2021 | 111 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 2 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 14 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 15 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 59 | 0.040 |
Why?
|
| Quality of Life | 1 | 2018 | 87 | 0.030 |
Why?
|
| Aged | 1 | 2018 | 703 | 0.030 |
Why?
|
| Adult | 1 | 2018 | 1567 | 0.020 |
Why?
|